<DOC>
	<DOCNO>NCT02183883</DOCNO>
	<brief_summary>To assess target activate EGFR HER2 mutation Non-Small Cell Lung Cancer ( NSCLC ) effective mutation truncal dominant mutation ( ≥50 % ) , oppose non-dominant ( ≥5 &lt; 50 % ) low frequency mutation ( &lt; 5 % ) . This trial available patient register TRACERx study ( NCT01888601 ) .</brief_summary>
	<brief_title>Deciphering Afatinib Response Resistance With INtratumour Heterogeneity</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>This therapeutic trial relevant patient involve TRACERx observational study . Subjects must willing biopsy relapse disease . Consent obtain TRACERx study . Procurement biopsy sample necessary time trial registration . However , patient must undergo biopsy prior commencement afatinib . Patients must tumours harbour sensitise EGFR mutation HER2 mutation least one biopsy recurrence , region primary sample . Written Informed consent DARWIN1 . ECOG performance status 03 No previous exposure EGFR TKI . No previous chemotherapy biological therapy advance set . Measurable disease RECIST v1.1 . At least 18 year age . Anticipated life expectancy least three month . Adequate organ function define follow baseline value : Absolute neutrophil count ( ANC ) ≥1.5x109/L Platelets ≥100x109/L Serum bilirubin ≤1.5 x upper limit normal ( ULN ) . In patient know Gilbert 's syndrome , total bilirubin ≤3xULN direct bilirubin ≤1.5xULN Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤3xULN ≤5x ULN liver metastases present Creatinine clearance must ≥30mL/min Women childbearing potential , men able father child , must willing practice acceptable method birth control trial 1 month end treatment . Women childbearing potential must negative pregnancy test within 14 day first dose trial medication . Suitable radical radiotherapy . Palliative radiotherapy within 2 week prior registration . Palliative radiotherapy solitary target lesion . Requirement intravenous feeding , active peptic ulcer , prior surgical procedure affect absorption medical comorbidity affect gastrointestinal absorption . Patients current preexist interstitial lung disease . Significant recent acute gastrointestinal abnormality diarrhoea major symptom e.g . Crohn 's disease , malabsorption , CTCAE v4.03 Grade ≥3 diarrhoea etiology baseline . Known hypersensitivity afatinib excipients . Patients rare hereditary condition galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Anticancer therapy include chemotherapy , radiation therapy , immunotherapy , biologic therapy , major surgery within 14 day prior start trial therapy . Known human immunodeficiency virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) syphilis infection . Subjects evidence hepatitis B virus clearance may enrol . History malignancy ; Exception : ( ) Subjects successfully treat diseasefree 3 year , ( b ) history completely resect nonmelanoma skin cancer , ( c ) successfully treat situ carcinoma , ( ) CLL stable remission , ( e ) indolent prostate cancer require antihormonal therapy histologically confirm tumor lesion clearly differentiate lung cancer target nontarget lesion eligible . The following cardiac abnormality : Corrected QT ( QTc ) interval ≥480 msecs History acute coronary syndrome ( include unstable angina ) within past 24 week Coronary angioplasty , stenting within past 24 week Class III , IV heart failure define New York Heart Association ( NYHA ) functional classification system History know arrhythmia ( except sinus arrhythmia ) within past 24 week Myocardial infarction within last 6 month Uncontrolled medical condition ( i.e. , diabetes mellitus , hypertension etc ) , psychological , familial , sociological , geographical condition permit compliance protocol ; unwillingness inability comply requirement trial , trial protocol provide inform consent . Pregnant , lactate actively breastfeed female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Afatinib</keyword>
	<keyword>Intra-tumour heterogeneity</keyword>
	<keyword>Clonal dominance</keyword>
	<keyword>Drug resistance</keyword>
	<keyword>EGFR</keyword>
	<keyword>HER2</keyword>
	<keyword>Phase 2</keyword>
</DOC>